J&J, Google venture arms line up to back protein degradation biotech EpiBiologics' $107M series B
By
January 8, 2026
Protein degradation biotech EpiBiologics has brought in $107 million in a star-studded series B round headed up by Johnson & Johnson's and Google's respective venture arms.
We congratulate Professor Jim Wells for his work on the foundational technology.